PharmaCyte Biotech
PMCB
23 hedge funds and large institutions have $420K invested in PharmaCyte Biotech in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 6 closing their positions.
0% more funds holding
Funds holding: 23 → 23 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
2.03% less ownership
Funds ownership: 8.4% → 6.38% (-2%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
34% less capital invested
Capital invested by funds: $632K → $420K (-$212K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$30.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14.5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.76K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$1.1K |
| 5 |
AWM
Accredited Wealth Management
Louisville,
Kentucky
|
+$50 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$119K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$30.4K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$22.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$21.2K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$3.56K |
PMCB Hedge Fund Activity: Q3 2025 in Review
23 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q3 2025, worth a combined $420K — down 34% from $632K a quarter earlier.
Fund positioning in PMCB was balanced in Q3 2025: 6 funds opened new positions, 6 closed out, 3 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $30.1K. The largest seller was Vanguard Group, cutting an estimated $119K.
- 23 institutional investors held PharmaCyte Biotech (PMCB) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $420K of PharmaCyte Biotech stock for Q3 2025, down 34% quarter-over-quarter.
- 6 funds opened new PharmaCyte Biotech positions in Q3 2025 and 6 closed out, a net change of 0 holders.
- The largest PharmaCyte Biotech buyer in Q3 2025 was Renaissance Technologies, an estimated $30.1K added.
- The largest PharmaCyte Biotech seller in Q3 2025 was Vanguard Group, an estimated $119K sold.
Based on aggregated 13F filings for Q3 2025.